Evelo Biosciences, Inc.
EVLO
$0.0003
-$0.0002-40.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.40% | -43.64% | -25.21% | -42.35% | -29.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.24% | -40.99% | -13.36% | -23.48% | -11.18% |
| Operating Income | 64.24% | 40.99% | 13.36% | 23.48% | 11.18% |
| Income Before Tax | 59.35% | 31.34% | 15.29% | 19.46% | 9.28% |
| Income Tax Expenses | -115.89% | 42.94% | 25.00% | 460.82% | -31.41% |
| Earnings from Continuing Operations | 59.55% | 30.95% | 15.14% | 17.84% | 9.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.55% | 30.95% | 15.14% | 17.84% | 9.39% |
| EBIT | 64.24% | 40.99% | 13.36% | 23.48% | 11.18% |
| EBITDA | 64.22% | 41.37% | 13.34% | 23.90% | 11.07% |
| EPS Basic | 87.43% | 53.14% | 58.97% | 59.97% | 55.19% |
| Normalized Basic EPS | 88.18% | 58.13% | 59.05% | 61.65% | 55.14% |
| EPS Diluted | 87.43% | 53.14% | 58.97% | 59.97% | 55.19% |
| Normalized Diluted EPS | 88.18% | 58.13% | 59.05% | 61.65% | 55.14% |
| Average Basic Shares Outstanding | 221.77% | 47.35% | 106.84% | 105.25% | 102.23% |
| Average Diluted Shares Outstanding | 221.77% | 47.35% | 106.84% | 105.25% | 102.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |